Research and Development news

05/16/12, Research and Development Bayer to Present Data on Late-Stage Development Oncology Compounds at ASCO 2012 First data from Phase III trial for regorafenib in gastrointestinal tumors (GIST) presented as Late-Breaking Abstract in Oral Abstract Session / Updated survival results from Phase III trial for Alpharadin (radium-223 chloride) in castration-resistant prostate cancer (CRPC) presented as Late-Breaking Abstract in Oral Abstract Session more

04/24/12, Research and Development Bayer expands targeted cancer therapy collaboration with Amgen more

04/03/12, Research and Development Phase III Trial of Regorafenib in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Meets Primary Endpoint of Improving Progression-Free Survival more

03/28/12, Research and Development Bayer to Present New Data on Oncology Pipeline New Preclinical Data Evaluating Innovative Compounds will be presented / Growing Research and Development Portfolio more

03/27/12, Research and Development Bayer HealthCare and Beijing’s Tsinghua University extend innovative drug discovery partnership more

04/08/11, Research and Development Bayer and Regeneron Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema Extends ophthalmology research & development program for VEGF Trap-Eye more

04/05/11, Research and Development In the Prevention of VTE in Acutely ill Patients, Rivaroxaban Compares Favorably with Enoxaparin but Does Not Show a Consistent Net Clinical Benefit MAGELLAN study meets primary efficacy endpoints of demonstrating non-inferiority in short-term use and superiority in long-term use / Primary analysis shows no consistent positive benefit-risk balance across heterogeneous patient population studied more

02/24/11, Research and Development Bayer and Onyx Initiate Phase III Trial of Nexavar® in Combination with Chemotherapy more

01/18/11, Research and Development Bayer and Regeneron start clinical Phase III trial to extend ophthalmology research & development program for VEGF Trap-Eye in Asia Collaboration with the Singapore Eye Research Institute to tackle a major eye disease common in Asia more

12/20/10, Research and Development Bayer and Regeneron Report Positive Results for VEGF Trap-Eye in Central Retinal Vein Occlusion and in Diabetic Macular Edema In Phase 3 study in CRVO, 56 percent of VEGF Trap-Eye patients gained at least 15 letters of vision compared to 12 percent in control group / In Phase 2 study in DME, patients in all VEGF Trap-Eye dose groups, including VEGF Trap-Eye dosed every two months, maintained or increased vision gains through 52-weeks more

05/21/10, Research and Development Nexavar® Data To Be Presented at 46th American Society of Clinical Oncology Annual Meeting more

More information about the topic Research and Development: